2021
Executive Summary Screening for Lung Cancer: Chest Guideline and Expert Panel Report
Mazzone PJ, Silvestri GA, Souter LH, Caverly TJ, Kanne JP, Katki HA, Wiener RS, Detterbeck FC. Executive Summary Screening for Lung Cancer: Chest Guideline and Expert Panel Report. CHEST Journal 2021, 160: 1959-1980. PMID: 34270965, PMCID: PMC8727851, DOI: 10.1016/j.chest.2021.07.003.Peer-Reviewed Original ResearchConceptsNational Lung Screening TrialLow-dose chest CTLung cancerCT screeningChest CTClinical questionsLow-dose CT screeningEvidence baseLow-dose chest CT screeningAdditional clinical questionsScreen-detected findingsScreening-eligible individualsGrading of RecommendationsChest CT screeningStandard of careImportant clinical questionsSystematic literature reviewExpert Panel ReportLow-dose CTCHEST GuidelineCessation interventionsCochrane LibraryGuideline publicationLiterature reviewConsensus statementScreening for Lung Cancer CHEST Guideline and Expert Panel Report
Mazzone PJ, Silvestri GA, Souter LH, Caverly TJ, Kanne JP, Katki HA, Wiener RS, Detterbeck FC. Screening for Lung Cancer CHEST Guideline and Expert Panel Report. CHEST Journal 2021, 160: e427-e494. PMID: 34270968, PMCID: PMC8727886, DOI: 10.1016/j.chest.2021.06.063.Peer-Reviewed Original ResearchConceptsNational Lung Screening TrialLow-dose chest CTLung cancerCT screeningChest CTClinical questionsLow-dose CT screeningEvidence baseLow-dose chest CT screeningAdditional clinical questionsScreen-detected findingsScreening-eligible individualsGrading of RecommendationsChest CT screeningStandard of careImportant clinical questionsSystematic literature reviewExpert Panel ReportLow-dose CTCHEST GuidelineCessation interventionsCochrane LibraryGuideline publicationLiterature reviewConsensus statement
2020
Management of Lung Nodules and Lung Cancer Screening During the COVID-19 Pandemic CHEST Expert Panel Report
Mazzone PJ, Gould MK, Arenberg DA, Chen AC, Choi HK, Detterbeck FC, Farjah F, Fong KM, Iaccarino JM, Janes SM, Kanne JP, Kazerooni EA, MacMahon H, Naidich DP, Powell CA, Raoof S, Rivera MP, Tanner NT, Tanoue LK, Tremblay A, Vachani A, White CS, Wiener RS, Silvestri GA. Management of Lung Nodules and Lung Cancer Screening During the COVID-19 Pandemic CHEST Expert Panel Report. CHEST Journal 2020, 158: 406-415. PMID: 32335067, PMCID: PMC7177089, DOI: 10.1016/j.chest.2020.04.020.Peer-Reviewed Original ResearchConceptsLung cancer screeningStage I non-small cell lung cancerNon-small cell lung cancerCell lung cancerCancer screeningLung nodule evaluationConsensus statementLung nodulesLung cancerClinical stage I non-small cell lung cancerNodule evaluationAnnual lung cancer screeningHigh-risk lung nodulesLung cancer screening programsCHEST Expert Panel ReportCurrent guideline recommendationsCancer screening programsPatient-related factorsCommon clinical scenariosCoronavirus disease 2019Balance of benefitsIndividual patient careCOVID-19 pandemicExpert Panel ReportPotential exposure
2018
Identifying Drivers of Multiple Readmissions After Pulmonary Lobectomy
Jean RA, Chiu AS, Hoag JR, Blasberg JD, Boffa DJ, Detterbeck FC, Kim AW. Identifying Drivers of Multiple Readmissions After Pulmonary Lobectomy. The Annals Of Thoracic Surgery 2018, 107: 947-953. PMID: 30336117, DOI: 10.1016/j.athoracsur.2018.08.070.Peer-Reviewed Original ResearchConceptsPulmonary lobectomyMultiple readmissionsSecond readmissionFirst readmissionIndex hospitalizationPostoperative infectionLung cancerPrimary diagnosisHeart diseaseClinical Classification Software codesNationwide Readmissions DatabaseTime of readmissionPostoperative arrhythmiasPostoperative complicationsPostoperative sepsisPerioperative periodPostoperative periodClinical factorsReadmissionLobectomyPatientsStudy periodImportant markerDiagnosisHealthcare quality
2017
Effectiveness of local therapy for stage I non–small-cell lung cancer in nonagenarians
Arnold BN, Thomas DC, Rosen JE, Salazar MC, Detterbeck FC, Blasberg JD, Boffa DJ, Kim AW. Effectiveness of local therapy for stage I non–small-cell lung cancer in nonagenarians. Surgery 2017, 162: 640-651. PMID: 28697883, DOI: 10.1016/j.surg.2017.04.025.Peer-Reviewed Original ResearchMeSH KeywordsAged, 80 and overCarcinoma, Non-Small-Cell LungConfidence IntervalsDatabases, FactualDisease-Free SurvivalFemaleGeriatric AssessmentHumansKaplan-Meier EstimateLogistic ModelsLung NeoplasmsMaleMultivariate AnalysisNeoplasm InvasivenessNeoplasm StagingOdds RatioPneumonectomyProportional Hazards ModelsRadiotherapyRegistriesRisk AssessmentSecondary PreventionSurvival AnalysisConceptsCell lung cancerLocal therapyLung cancerStage IRelative survivalStereotactic body radiation therapyNational Cancer DatabaseBetter overall survivalBody radiation therapyOlder patientsOverall survivalPatient ageYounger patientsOverall mortalityPrimary outcomeCancer DatabaseTreatment outcomesTreatment decisionsRadiation therapyPatientsTherapyCancerNonagenariansTreatmentSurvivalValidating the Thoracic Revised Cardiac Risk Index Following Lung Resection
Thomas DC, Blasberg JD, Arnold BN, Rosen JE, Salazar MC, Detterbeck FC, Boffa DJ, Kim AW. Validating the Thoracic Revised Cardiac Risk Index Following Lung Resection. The Annals Of Thoracic Surgery 2017, 104: 389-394. PMID: 28499655, DOI: 10.1016/j.athoracsur.2017.02.006.Peer-Reviewed Original ResearchConceptsAdditional cardiac evaluationIschemic heart diseaseLarger multi-institutional datasetsCardiac complicationsLung resectionRenal comorbiditiesCardiac evaluationCerebrovascular diseaseHeart diseaseRisk factorsMulti-institutional datasetSurgeons National Surgical Quality Improvement Program datasetNational Surgical Quality Improvement Program datasetCardiac complication ratesMajor cardiac complicationsPreoperative risk factorsUnderwent pneumonectomyCardiac indexComplication ratePrimary outcomeRisk classesMalignant diseaseOpen procedureAmerican CollegeHigh risk
2015
Multimodality therapy for locally advanced thymomas: A propensity score–matched cohort study from the European Society of Thoracic Surgeons Database
Leuzzi G, Rocco G, Ruffini E, Sperduti I, Detterbeck F, Weder W, Venuta F, Van Raemdonck D, Thomas P, Facciolo F, Group E. Multimodality therapy for locally advanced thymomas: A propensity score–matched cohort study from the European Society of Thoracic Surgeons Database. Journal Of Thoracic And Cardiovascular Surgery 2015, 151: 47-57.e1. PMID: 26403869, DOI: 10.1016/j.jtcvs.2015.08.034.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overAsiaChemotherapy, AdjuvantChi-Square DistributionChildDatabases, FactualDisease ProgressionDisease-Free SurvivalEuropeFemaleHumansKaplan-Meier EstimateMaleMiddle AgedMultivariate AnalysisNeoadjuvant TherapyNeoplasm Recurrence, LocalNeoplasm StagingNorth AmericaPropensity ScoreProportional Hazards ModelsRadiotherapy, AdjuvantRetrospective StudiesRisk AssessmentRisk FactorsSocieties, MedicalThymectomyThymomaThymus NeoplasmsTime FactorsTreatment OutcomeTumor BurdenYoung AdultConceptsRelapse-free survivalAdvanced thymomaMultimodality therapyOverall survivalT classificationPropensity score-matched cohort studyMultivariate Cox proportional hazards modelPropensity score-matched analysisCox proportional hazards modelPathologic T classificationStage III thymomaThoracic Surgeons databaseSignificant survival advantageSpecific pathologic featuresStrong predictive factorProportional hazards modelInduction therapyAdjuvant therapyPT3 tumorsCohort studyIndependent predictorsPrognostic impactMultivariable analysisPathologic featuresPredictive factorsComponents Necessary for High-Quality Lung Cancer Screening American College of Chest Physicians and American Thoracic Society Policy Statement
Mazzone P, Powell CA, Arenberg D, Bach P, Detterbeck F, Gould MK, Jaklitsch MT, Jett J, Naidich D, Vachani A, Wiener RS, Silvestri G. Components Necessary for High-Quality Lung Cancer Screening American College of Chest Physicians and American Thoracic Society Policy Statement. CHEST Journal 2015, 147: 295-303. PMID: 25356819, PMCID: PMC4502754, DOI: 10.1378/chest.14-2500.Peer-Reviewed Original ResearchMeSH KeywordsHealth PolicyHumansLung NeoplasmsMass ScreeningRisk AssessmentSolitary Pulmonary NoduleTomography, X-Ray ComputedConceptsLung cancer screening programsCancer screening programsLung cancer screeningAmerican Thoracic SocietyCancer screeningScreening programChest PhysiciansAmerican CollegeHigh-quality lung cancer screening programThoracic Oncology NetworkEvidence-based reviewLow-dose chest CT scansChest CT scanAmerican Cancer SocietyLung cancerComponents of screeningEssential program componentsThoracic SocietyOncology NetworkCancer SocietyCT scanProgram componentsPreventive oncologyAmerican SocietyScreening facility
2012
American College of Chest Physicians and Society of Thoracic Surgeons Consensus Statement for Evaluation and Management for High-Risk Patients With Stage I Non-small Cell Lung Cancer
Donington J, Ferguson M, Mazzone P, Handy J, Schuchert M, Fernando H, Loo B, Lanuti M, de Hoyos A, Detterbeck F, Pennathur A, Howington J, Landreneau R, Silvestri G, Surgeons F. American College of Chest Physicians and Society of Thoracic Surgeons Consensus Statement for Evaluation and Management for High-Risk Patients With Stage I Non-small Cell Lung Cancer. CHEST Journal 2012, 142: 1620-1635. PMID: 23208335, DOI: 10.1378/chest.12-0790.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerStage I non-small cell lung cancerHigh-risk patientsCell lung cancerChest PhysiciansTreatment optionsLung cancerAmerican CollegeStereotactic body radiation therapySevere medical comorbiditiesThoracic Oncology NetworkAlternative treatment optionMore indolent tumorsBody radiation therapyRisk-benefit decisionsInterventional riskMedical comorbiditiesNonoperative therapyRespiratory failureInvolved lobeMediastinal lymphProcedural morbidityRegional recurrenceSublobar resectionRadiographic stagingOutcomes for Lung Transplantation for Lung Cancer in the United Network for Organ Sharing Registry
Ahmad U, Wang Z, Bryant AS, Kim AW, Kukreja J, Mason DP, Bermudez CA, Detterbeck FC, Boffa DJ. Outcomes for Lung Transplantation for Lung Cancer in the United Network for Organ Sharing Registry. The Annals Of Thoracic Surgery 2012, 94: 935-941. PMID: 22835555, DOI: 10.1016/j.athoracsur.2012.04.069.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinoma, Bronchiolo-AlveolarAdultAnalysis of VarianceCause of DeathDisease-Free SurvivalFemaleGraft RejectionGraft SurvivalHospital MortalityHumansImmunohistochemistryKaplan-Meier EstimateLung NeoplasmsLung TransplantationMaleMiddle AgedNeoplasm InvasivenessNeoplasm StagingPatient SelectionPreoperative CarePrognosisProportional Hazards ModelsRegistriesRetrospective StudiesRisk AssessmentSurvival AnalysisTissue and Organ ProcurementTreatment OutcomeConceptsLung transplantationBronchoalveolar carcinomaLung transplantUnited NetworkLung cancerDouble lung transplantOrgan Sharing databaseOrgan Sharing registrySubgroup of patientsMaximum survival advantageBAC patientsSecond percentExpiratory volumeMedian survivalTransplantation cohortSharing databasePoor prognosisPure adenocarcinomaPathology reportsInvasive tumorsSurvival advantageExtended survivalTransplantationPatientsTransplantCharacteristics Associated With the Use of Nonanatomic Resections Among Medicare Patients Undergoing Resections of Early-Stage Lung Cancer
Kim AW, Detterbeck FC, Boffa DJ, Decker RH, Soulos PR, Cramer LD, Gross CP. Characteristics Associated With the Use of Nonanatomic Resections Among Medicare Patients Undergoing Resections of Early-Stage Lung Cancer. The Annals Of Thoracic Surgery 2012, 94: 895-901. PMID: 22835558, PMCID: PMC3501201, DOI: 10.1016/j.athoracsur.2012.04.091.Peer-Reviewed Original ResearchMeSH KeywordsAge DistributionAgedAged, 80 and overCarcinoma, Non-Small-Cell LungConfidence IntervalsDisease-Free SurvivalEthnicityFemaleHumansLogistic ModelsLungLung NeoplasmsMaleMedicareMultivariate AnalysisNeoplasm InvasivenessNeoplasm StagingOdds RatioPneumonectomyPostoperative ComplicationsPrognosisRetrospective StudiesRisk AssessmentSEER ProgramSex DistributionSurvival AnalysisUnited StatesConceptsChronic obstructive pulmonary diseaseNonanatomic resectionStage I NSCLCSurgical resectionSurgical approachLung cancerNational Cancer Institute's SurveillanceEarly-stage lung cancerPatients 67 yearsPrimary tumor statusObstructive pulmonary diseaseCell lung cancerHospital factorsLung resectionWedge resectionClinical factorsPulmonary diseaseMultivariable analysisTumor sizeLarge tumorsHospital characteristicsTumor statusMedicare patientsResectionPatientsCancer, concepts, cohorts and complexity: avoiding oversimplification of overdiagnosis
Detterbeck FC. Cancer, concepts, cohorts and complexity: avoiding oversimplification of overdiagnosis. Thorax 2012, 67: 842. PMID: 22628119, DOI: 10.1136/thoraxjnl-2012-201779.Peer-Reviewed Original ResearchCurrent Status of Lung Cancer Screening
Ahmad U, Detterbeck FC. Current Status of Lung Cancer Screening. Seminars In Thoracic And Cardiovascular Surgery 2012, 24: 27-36. PMID: 22643659, DOI: 10.1053/j.semtcvs.2012.01.014.Peer-Reviewed Original Research
2011
Long-term survival after lung resection for non–small cell lung cancer with circulatory bypass: A systematic review
Muralidaran A, Detterbeck FC, Boffa DJ, Wang Z, Kim AW. Long-term survival after lung resection for non–small cell lung cancer with circulatory bypass: A systematic review. Journal Of Thoracic And Cardiovascular Surgery 2011, 142: 1137-1142. PMID: 21864854, DOI: 10.1016/j.jtcvs.2011.07.042.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerCell lung cancerLong-term survivalAdvanced non-small cell lung cancerCirculatory bypassLung cancerLung resectionMultivariate analysisSystematic reviewFavorable long-term survivalUnfavorable long-term survivalWorse long-term survivalCox proportional hazards modelUnplanned cardiopulmonary bypassPrimary end pointKaplan-Meier methodCox regression modelProportional hazards modelPerioperative mortalityExtended resectionCardiopulmonary bypassClinical variablesExclusion criteriaResectionHazards model
2010
High expression of BCL-2 predicts favorable outcome in non-small cell lung cancer patients with non squamous histology
Anagnostou VK, Lowery FJ, Zolota V, Tzelepi V, Gopinath A, Liceaga C, Panagopoulos N, Frangia K, Tanoue L, Boffa D, Gettinger S, Detterbeck F, Homer RJ, Dougenis D, Rimm DL, Syrigos KN. High expression of BCL-2 predicts favorable outcome in non-small cell lung cancer patients with non squamous histology. BMC Cancer 2010, 10: 186. PMID: 20459695, PMCID: PMC2875218, DOI: 10.1186/1471-2407-10-186.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAgedBiomarkers, TumorCarcinoma, Large CellCarcinoma, Non-Small-Cell LungCarcinoma, Squamous CellCell DifferentiationCohort StudiesConnecticutFemaleGreeceHumansKaplan-Meier EstimateLung NeoplasmsMaleMiddle AgedNeoplasm StagingPredictive Value of TestsProportional Hazards ModelsProto-Oncogene Proteins c-bcl-2Reproducibility of ResultsRetrospective StudiesRisk AssessmentRisk FactorsTime FactorsTreatment OutcomeUp-RegulationConceptsNon-small cell lung cancer patientsCell lung cancer patientsNon-squamous tumorsLung cancer patientsBcl-2 expressionNSCLC patientsCancer patientsBcl-2Favorable outcomeIndependent cohortSmall cell lung cancer patientsIndependent lower riskNon-squamous histologySubgroup of patientsHigh expressersSquamous cell carcinomaHigh Bcl-2 expressionBcl-2 protein levelsSquamous histologyMedian survivalPrognostic factorsValidation cohortCell carcinomaPathological characteristicsPrognostic stratification
2009
Impact of Preoperative Chemotherapy on Pulmonary Function Tests in Resectable Early-Stage Non-small Cell Lung Cancer
Rivera MP, Detterbeck FC, Socinski MA, Moore DT, Edelman MJ, Jahan TM, Ansari RH, Luketich JD, Peng G, Monberg M, Obasaju CK, Gralla RJ. Impact of Preoperative Chemotherapy on Pulmonary Function Tests in Resectable Early-Stage Non-small Cell Lung Cancer. CHEST Journal 2009, 135: 1588-1595. PMID: 19188545, DOI: 10.1378/chest.08-1430.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntineoplastic Combined Chemotherapy ProtocolsCarboplatinCarcinoma, Non-Small-Cell LungChemotherapy, AdjuvantCisplatinConfidence IntervalsDeoxycytidineDose-Response Relationship, DrugDrug Administration ScheduleFemaleFollow-Up StudiesGemcitabineHumansLung NeoplasmsMaleMaximum Tolerated DoseMiddle AgedNeoadjuvant TherapyNeoplasm StagingPaclitaxelPneumonectomyPreoperative CareProbabilityRespiratory Function TestsRisk AssessmentSurvival AnalysisConceptsNon-small cell lung cancerCell lung cancerSurgical resectionLung cancerPulmonary toxicityResectable early stage non-small cell lung cancerEarly-stage non-small cell lung cancerRandomized phase 2 trialPulmonary function test resultsSecondary end pointsCombination of gemcitabinePhase 2 trialPulmonary function testsGemcitabine-based chemotherapyFunction test resultsTotal lung capacityEligible patientsNonplatinum regimensDyspnea scoreInterstitial pneumonitisPreoperative chemotherapyFunction testsSmoking statusClinical symptomsPreoperative setting
2004
Systematic Review Evaluating the Timing of Thoracic Radiation Therapy in Combined Modality Therapy for Limited-Stage Small-Cell Lung Cancer
Fried DB, Morris DE, Poole C, Rosenman JG, Halle JS, Detterbeck FC, Hensing TA, Socinski MA. Systematic Review Evaluating the Timing of Thoracic Radiation Therapy in Combined Modality Therapy for Limited-Stage Small-Cell Lung Cancer. Journal Of Clinical Oncology 2004, 22: 4837-4845. PMID: 15570087, DOI: 10.1200/jco.2004.01.178.Peer-Reviewed Original ResearchMeSH KeywordsCarcinoma, Non-Small-Cell LungChemotherapy, AdjuvantCombined Modality TherapyConfidence IntervalsDose Fractionation, RadiationDose-Response Relationship, RadiationHumansLung NeoplasmsNeoplasm StagingOdds RatioPneumonectomyPrognosisRadiotherapy DosageRadiotherapy, AdjuvantRandomized Controlled Trials as TopicRisk AssessmentSurvival AnalysisTreatment OutcomeConceptsThoracic radiation therapyPlatinum-based chemotherapyRisk ratioRadiation therapyLS-SCLCLung cancerLimited-stage small cell lung cancerSmall cell lung cancerHyperfractionated radiation therapyLimited-Stage SmallProphylactic cranial irradiationCombined modality therapyCell lung cancerCranial irradiationChemotherapy regimensChemotherapeutic regimenModality therapySurvival benefitRandomized trialsDaily fractionationSubset analysisRadiation fractionationRT relativeRisk differenceChemotherapy